Abstract: A user equipment (UE) is configured to use multiple beams for transmission or reception. The UE receives, from a base station, at least one medium access control (MAC) control element (CE) that indicates multiple activated transmission configuration indicator (TCI) states, receives, from the base station, at least one downlink control information (DCI) indicating a subset of TCI states of the multiple activated TCI states, wherein the MAC CE and the DCI are part of a TCI configuration, and wherein the subset of TCI states corresponds to multiple transmission and reception points (TRPs) of a wireless network, maps the subset of TCI states to the corresponding multiple TRPs based on the TCI configuration and selects a beam used for transmission or reception based on one mapped TCI state of the mapped subset of TCI states.

Abstract: This disclosure relates to apparatuses and methods for providing and managing reception feedback for multicast and broadcast services (MBS). A base station (BS) may select and communicate, to a group of user equipment devices (UEs), configuration parameters for MBS communications, such as an indication of an MBS retransmission procedure for an MBS service. The BS may also transmit, to the group of UEs, an MBS data communication. A first UE may receive the MBS data communication, but may determine that the received MBS data communication is corrupted. The first UE may respond by transmitting, to the BS, a negative-acknowledgement (NACK) message. The BS may retransmit the MBS data communication either as an MBS transmission or as a unicast transmission, based on the configuration parameters. The first UE may monitor the appropriate resources to receive the retransmitted MBS data communication, based on the configuration parameters.

Abstract: The present application relates to devices and components including apparatus, systems, and methods to provide repetition of system information block type 1 in a plurality of slots.

Abstract: The present application relates to devices and components including apparatus, systems, and methods for radio-link monitoring operations in radio networks that include beam-specific bandwidth parts.

Abstract: Techniques discussed herein facilitate generation of uplink control information for Enhanced Physical Uplink Control Channel (PUCCH) Format(s) (EPF(s)). One example embodiment employable in a User Equipment (UE) is configured to: determine Hybrid Automatic Repeat reQuest-Acknowledgment (HARQ-ACK) information; generate a PUCCH for a BandWidth Part (BWP) based at least in part on the HARQ-ACK information, wherein the PUCCH has an EPF; determine a PUCCH resource for the PUCCH and a first PRB index for the PUCCH, wherein the PUCCH resource is determined based at least in part on an index of a first Control Channel Element (CCE) of an associated Physical Downlink Control Channel (PDCCH) and a number of CCEs in a Control Resource Set (CORESET) of the associated PDCCH; and map the PUCCH to at least one PUCCH interlace based on the PUCCH resource and the first PRB index for the PUCCH.

Abstract: A user equipment (UE), a base station (e.g., next generation NodeB (gNB)), or other network component can operate to configure a beam failure recovery (BFR) timing based on a time offset and a number of symbols in a BFR procedure, as well as enable beam switching and bandwidth part (BWP) switching to be correlated. A beam failure recovery request (BFRQ) can be processed or transmitted in response to a detection of a beam failure. A beam failure recovery response (BFRR) can be generated via a physical downlink control channel (PDCCH) based on at least four slots after the BFRQ and a time offset for a non-terrestrial network (NTN).

Abstract: Aspects of the present disclosure are related to a method performed by a user equipment (UE). The method includes selecting a candidate resource set with a plurality of candidate resources from a resource selection window. The plurality of candidate resources includes a reserved resource that is reserved by at least one other UE. The method includes determining that the reserved resource is associated with a priority level PRX that is higher than a transmission priority level PTX associated with the UE. The method further includes excluding the reserved resource from the candidate resource set based at least in part on the determining.

Abstract: Systems, methods, and circuitries are provided for supporting blind retransmission. In one example, a method includes determining one or more communication parameters for use in communicating with a user equipment (UE) based on whether hybrid automatic repeat request (HARQ) feedback is enabled for the UE; and using at least one of the one or more communication parameters when HARQ feedback is determined to be enabled.

Abstract: A method and apparatus of a device that determines a physical downlink shared channel scheduling resource for a user equipment device and a base station is described. In an exemplary embodiment, the device selects a plurality of component carriers from a pool of available component carriers associated with a wireless link established between the user equipment device and the base station. In addition, the device selects a virtual component carrier from the plurality of component carriers. Furthermore, the device determines a physical downlink shared channel scheduling resource based on at least the virtual component carrier.

Abstract: The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection comprising crystalline entecavir as the pharmaceutically active ingredient and one or more pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have improved stability compared to that of amorphous entecavir under the conditions of light, high temperature and high humidity.

Abstract: The present invention provides an anti-Coxsackie virus oxadiazole compound as represented by formula (I), or the pharmaceutically acceptable salt thereof, a preparation method, a pharmaceutical composition, and use thereof, wherein R is CH3 or CF3; R? and R? are respectively H, alkyl or halogen; A is O or S; n is a number from 1 to 6; X is O, S or NH; Y is alkyl, unsubstituted cycloalkyl, mono-substituted cycloalkyl, disubstituted cycloalkyl, poly-substituted cycloalkyl, unsubstituted aryl, mono-substituted aryl, disubstituted aryl, poly-substituted aryl, unsubstituted 5-6 membered heterocyclyl, mono-substituted 5-6 membered heterocyclyl, disubstituted 5-6 membered heterocyclyl, or poly-substituted 5-6 membered heterocyclyl. Compared to prior art, the oxadiazole compound of the present invention has excellent anti-Coxsackie virus activity, lower toxicity and high safety.

Abstract: Provided are a linezolid intermediate and the preparation method thereof and a method for synthesizing linezolid. The structure of the intermediate is shown as formula F2, wherein the compound is prepared by a condensation reaction of (S)—N-(3-chloro-2-hydroxy-1-propyl) acetamide and the compound shown in formula F4. In the preparation methods of the compound shown in formula F2 and linezolid, the reaction system is mild, side reactions are few and the product yield is high.

Abstract: The present invention relates to a crystalline form of entecavir and its process for preparation, and provides a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of entecavir. Furthermore, the present invention also provides a use of the crystalline form of entecavir in preparation for a medicament for the treatment of hepatitis B viral infections. The present invention is beneficial toe preparations for pharmaceutical formulations and enhancements of its bioavailability.

Abstract: The present invention provides an anti-Coxsackie virus oxadiazole compound as represented by formula (I), or the pharmaceutically acceptable salt thereof, a preparation method, a pharmaceutical composition, and use thereof, wherein R is CH3 or CF3; R? and R? are respectively H, alkyl or halogen; A is O or S; n is a number from 1 to 6; X is O, S or NH; Y is alkyl, unsubstituted cycloalkyl, mono-substituted cycloalkyl, disubstituted cycloalkyl, poly-substituted cycloalkyl, unsubstituted aryl, mono-substituted aryl, disubstituted aryl, poly-substituted aryl, unsubstituted 5-6 membered heterocyclyl, mono-substituted 5-6 membered heterocyclyl, disubstituted 5-6 membered heterocyclyl, or poly-substituted 5-6 membered heterocyclyl. Compared to prior art, the oxadiazole compound of the present invention has excellent anti-Coxsackie virus activity, lower toxicity and high safety.

Abstract: The present invention relates to an intermediate (12) of lycopene of 2,6,10-trimethyl-1,1-dialkoxyl-3,5,9-undecantriene of formula, (12) and its intermediate of 4-methyl-5,5-dialkoxyl-1-pentenyl-1-phosphonic acid dialkyl ester of formula (10), and their preparation methods. The process route is simple, the starting materials are available easily, the cost is low, and it is valuable in industry.

Abstract: The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection comprising crystalline entecavir as the pharmaceutically active ingredient and one or more pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have improved stability compared to that of amorphous entecavir under the conditions of light, high temperature and high humidity.

Abstract: The invention relates to a novel important lycopene intermediate 3,7,11-trimethyl-1,3,6,10-tetraene-dodecyl diethyl phosphonate. A current lycopene intermediate 2,4,6,10-tetra-double bond pentadec-carbon phosphonate is difficult to synthesize. The invention provides a novel intermediate, which has the following synthesis steps of: preparing 2,6,10-trimethyl-3,5,9-undecane triene-1-aldehyde from pseudoionone; preparing 2,6,10-trimethyl-2,5,9-undecane triene-1-aldehyde from the 2,6,10-trimethyl-3,5,9-undecane triene-1-aldehyde; and subjecting the 2,6,10-trimethyl-2,5,9-undecane triene-1-aldehyde and tetraethyl methylenediphosphonate to condensation reaction to obtain target product. The invention can generate novel intermediate from raw material pseudoionone only by four reactions, thus the reactions are easy to control and great industrial value are achieved.

Abstract: The invention discloses an intermediate 1-methoxyl-2,6,10-trimethyl-1,3,5, 9-undec-tetraene, and a preparation method and uses thereof. In the synthesis method for the current lycopene intermediate 2-pos double bond C-14 aldehyde (2,6,10-trimethyl-2,5,9-undecatriene-1-aldehyde), expensive methyl iodide, polluting dimethyl sulphide and dangerous strong base are needed, so that the method is hardly applied to industrial production. The invention provides a new compound 1-methoxyl-2,6,10-trimethyl-1,3,5,9-undec-tetraene, and pure 2-pos double bond C-14 aldehyde can be prepared by hydrolyzing and refining the compound. The synthetic route is simplified and the great suitability for industrial production is achieved.

Abstract: The present invention relates to 2,6,10-trimethyl-3,5,9-undecatrienyl-1-aldehyde represented by formula (3), and a method for preparing this intermediate. The process route of the present invention is simple, the starting materials are available easily, and the cost is low.

Abstract: Provided are a linezolid intermediate and the preparation method thereof and a method for synthesizing linezolid. The structure of the intermediate is shown as formula F2, wherein the compound is prepared by a condensation reaction of (S)—N—(3-chloro-2-hydroxy-1-propyl) acetamide and the compound shown in formula F4. In the preparation methods of the compound shown in formula F2 and linezolid, the reaction system is mild, side reactions are few and the product yield is high.